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Abstract Kaletra® (Abott Laboratories) is a co-formulated
medication used in the treatment of HIV-1-infected chil-
dren, and it contains the two antiretroviral protease inhibitor
drugs lopinavir and ritonavir. We validated two new
ultrafast and high-throughput mass spectrometric assays to
be used for therapeutic drug monitoring of lopinavir and
ritonavir concentrations in whole blood and in plasma from
HIV-1-infected children. Whole blood was blotted onto
dried blood spot (DBS) collecting cards, and plasma was
collected simultaneously. DBS collecting cards were
extracted by an acetonitrile/water mixture while plasma
samples were deproteinized with acetone. Drug concen-
trations were determined by matrix-assisted laser
desorption/ionization-triple quadrupole tandem mass spec-
trometry (MALDI-QqQ-MS/MS). The application of DBS
made it possible to measure lopinavir and ritonavir in whole
blood in therapeutically relevant concentrations. The
MALDI-QqQ-MS/MS plasma assay was successfully
cross-validated with a commonly used high-performance
liquid chromatography (HPLC)–ultraviolet (UV) assay for
the therapeutic drug monitoring (TDM) of HIV-1-infected
patients, and it showed comparable performance character-
istics. Observed DBS concentrations showed as well, a good
correlation between plasma concentrations obtained by
MALDI-QqQ-MS/MS and those obtained by the HPLC-
UVassay. Application of DBS for TDM proved to be a good
alternative to the normally used plasma screening. Moreover,
collection of DBS requires small amounts of whole blood
which can be easily performed especially in (very) young
children where collection of large whole blood amounts
is often not possible. DBS is perfectly suited for TDM of
HIV-1-infected children; but nevertheless, DBS can also
easily be applied for TDM of patients in areas with
limited or no laboratory facilities.
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Introduction
Protease inhibitors (PI) belong to a class of pharmaceuticals
used in the treatment of the human immunodeficiency virus
infection (HIV) [1]. This class of protease inhibitor drugs
inhibits the viral HIV-1 protease enzyme, which processes
viral polyproteins which are essential for the completion of
the HIV viral life cycle. PI drugs are used within the
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combined antiretroviral therapy, a therapy which has
significantly improved the decrease in morbidity and
mortality for HIV-infected patients [2]. Kaletra® (Abbott)
is a co-formulation, containing the two protease inhibitors
lopinavir (LPV, 80 mg/mL) and ritonavir (RTV, 20 mg/mL).
This co-formulation is used in pediatric HIV-1 pediatric
treatment. RTV acts to boost up the lopinavir plasma
concentration by inhibition of the cytochrome P450
CYP3A isozymes [3] and the active transport by the
P-glycoprotein [4]. Patient’s drug intake compliance is very
important in HIV treatment, and the patient’s compliance
with the drug regimen can be monitored by determination
of the LPV and RTV plasma concentration levels. More
importantly, plasma concentrations of HIV protease
inhibitors are used to optimize dosing with these drugs for
each individual patient (therapeutic drug monitoring
(TDM)), which is in particular important for HIV-infected
children because of the profound changes in drug pharma-
cokinetics during development and maturation of the child.
Patient compliance to the HIV drugs regimen and TDM
is in general monitored by analyses of plasma or serum;
sometimes, also another body fluid such as saliva [5] is
used. Heine et al. [6] and Koal et al. [7] used both DBS for
the quantitative determination of PI concentrations by
LC-MS/MS. The DBS assay was first described by Guthrie
[8] in the 1960s and was primarily used to screen neonates
for metabolic diseases. DBS assays are not only applied for
screening of metabolic diseases in neonates but in general
can also be used to determine drug concentrations in whole
blood. Especially, DBS assays have been applied for the
determination of concentrations of antimalarials [9], anti-
epileptics [10], and antiretrovirals [7].
Whole blood is collected from either heel or finger prick
or by collection by vena-puncture. The whole blood is then
blotted onto a DBS collection card. After the whole blood
spots have been dried, a disk is punched out from the center
of the DBS, and PI are extracted from the disk with
appropriate solvents and extracts are analyzed. Over the last
decades, several DBS assays have been applied for
screening of metabolic disorders [11].
Analytical assays used for the determination of LPV,
RTV, and other PI in general are high-performance liquid
chromatography (HPLC) with ultraviolet (UV) [12]
detection, electrospray ionization–mass spectrometry
(ESI-MS) [13, 14] and tandem mass spectrometry
(ESI-MS/MS) [7, 15–18], and matrix-assisted laser
desorption/ionization-triple quadrupole tandem mass spec-
trometry (MALDI-QqQ-MS/MS) [19]. MALDI-QqQ-MS/
MS is a relative new technique that combines two known
aspects of mass spectrometry, MALDI and triple quadru-
pole mass spectrometry (QqQ), into a novel merged mass
spectrometric technique. Biological samples are mixed
with a solution containing the MALDI matrix, which is
typically a small molecule that absorbs the energy of the
laser and assists with desorption and gentle ionization of
the analyte. A small aliquot (0.25–1.5 μL) of the sample/
matrix solution is then spotted onto a MALDI (stainless
steel) target plate. The spots are dried at ambient
temperature and analyzed by ionization by a high
repetition rate solid state UV laser (1 kHz, 349 nm). The
produced ions are then analyzed using multiple reaction
monitoring (MRM). The MALDI-QqQ-MS/MS technique
does not necessarily require liquid chromatographic
separation of samples prior to mass MRM analyses.
Therefore, an analysis time of MALDI-QqQ-MS/MS is
primarily determined by the amount of laser shots required
to obtain a reproducible MRM, the raster speed of the
laser, and the repetition rate of the laser. Using our
settings, the analysis takes 5 s per sample or even less
(depending on laser speed). The MALDI-QqQ-MS/MS
assay has been previously used to determine the concen-
trations of different drug types [20], antiretroviral drugs
[21, 22], benzodiazepines [23], beta-blockers, and anti-
biotics [24] but was also successfully used as a screening
tool in enzyme kinetic studies [25]. In this study, we
present two newly developed MALDI-QqQ-MS/MS
assays for ultrafast and high-throughput monitoring of
lopinavir and ritonavir drug concentrations in plasma and
in whole blood (DBS) from HIV-1-infected children. The
new assays were validated according to the FDA guide-
lines [26], and tested and applied for its clinical use by
analyses of DBS and plasma samples from a cohort study
of HIV-1-infected children. Observed plasma concentra-
tion levels of LPV and RTV by the MALDI-QqQ-MS/MS
plasma assay were also cross-validated with a validated
HPLC-UV assay.
Materials and methods
Chemicals and reagents
Investigated PI drugs were a kindly donation from
pharmaceutical companies: LPV and RTV by Abbott
Laboratories (IL, USA) and the internal standard nelfinavir
(NFV) by Pfizer (Groton, CT, USA). A primary stock
solution of LPV and RTV was prepared in methanol and
contained 200 μmol/L LPV and RTV, while a second
primary stock solution also prepared in methanol contained
200 μmol/L of the internal standard NFV, respectively. All
solvents used were obtained from commercial sources and
were of LC-MS grade (Biosolve, Valkenswaard, the
Netherlands), and other chemicals were of ACS grade from
Sigma Aldrich (Zwijndrecht, the Netherlands). Chemical
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structures of lopinavir, ritonavir, and used internal standard
nelfinavir are illustrated in Fig. 1.
Preparation of calibrators and calibration curves
Whole blood-based calibrators for DBS analyses
Calibrators for the DBS assay were prepared by dilution
of the primary stock solution with drug-free whole blood
(EDTA) from healthy donors that were obtained from the
local blood bank (Sanquin Blood Supply Foundation,
Rotterdam, the Netherlands). Whole blood-based calibra-
tors yielded following concentrations: 50, 25, 10, 5.0,
2.5, 1.0, 0.5, and 0.25 μmol/L LPV and RTV. From the
calibrators, an aliquot of 25 μL were spotted (n=4) onto
FTA PK DBS collecting cards from GE Healthcare
(Piscataway, NJ, USA). DBS collecting cards were dried
overnight at room temperature. Two disks (7 mm diame-
ter) were punched out from two different DBS, and
punches were transferred into a safe-lock micro tube
(1.5 mL, Eppendorf) and extracted with 250 μL of a
acetonitrile/water mixture 80:20 (v/v) containing 5 μmol/L
nelfinavir as internal standard (IS) for 30 min in an
ultrasonic bath. DBS extracts were centrifuged for 5 min
at room temperature (2,000×g) to remove precipitated
proteins. From the supernatants, 20 μL was mixed with
20 μL of MALDI matrix α-cyano-4-hydroxycinnamic
acid (α-CHCA), Agilent Technologies; 6.2 mg/mL in
methanol/acetonitrile/water 36:56:8 (v/v/v), pH=2.5 sup-
plemented with 1 mmol/L sodium iodide (NaI) and 1.5 μL
of the supernatant/MALDI matrix mixtures were spotted
(n=5) on an Opti-TOF 96-well stainless steel target plate
(123×81 mm; MDS Analytical Technologies, Concord,
Canada), and sample spots were dried at room temperature
for 5 min.
Plasma-based calibrators
Plasma-based calibrators were prepared from drug-free
plasma harvested from the drug-free whole blood collected
of healthy donors, which were also used for development of
the DBS assay. The plasma was prepared by centrifugation
of whole blood for 10 min at a temperature of 4 °C
(400×g). Plasma-based calibrators were prepared by spiking
with LPV and RTV and yielded the following calibrators: 4,
1, 0.5, 0.2, 0.1, and 0.05 μmol/L, and a blank. From each
calibrator, two aliquots of 10 μL were spiked with 5 μL of
an IS solution and were deproteinized by the addition of
85 μL of acetone. Precipitated proteins were removed by
centrifugation for 5 min at room temperature (2,000×g).
The supernatants (20 μL) were mixed with α-CHCA
solution (20 μL), 1.5 μL of the supernatant/matrix mixture
was spotted (n=5), and the resulting sample spots were
dried at room temperature for 5 min.
MALDI-triple quadrupole tandem mass spectrometry
MALDI-QqQ-MS/MS analyses were conducted on a Flash-
quant Workstation combined with a 4000 API mass analyzer
(MDS Analytical Technologies) operating in the positive
ionization mode. MS/MS analyses were carried out by MRM
at unit resolution. MRM parameters of the sodium adducts of
analyte molecules (M + Na)+ used in this study were LPV
(m/z 651.4>439.4), RTV (m/z 743.4>573.6), and NFV
(m/z 590.0>338.2) and collision energies were 52, 50, and
50 V for LPV, RTV, and NFV, respectively. Optimized
MALDI-QqQ-MS/MS instrument parameters were as fol-
lows: laser power 60%, target plate voltage 60 V, skimmer
voltage 0 V, CAD gas 6 arbitrary units (collision gas),
collision cell energy exit potential (CXP) 10 V, source gas 10
arbitrary units, dwell time 20 ms, and laser speed 1 mm/s.
m/z 651.4> m/z 439.4 m/z 590.0> m/z 338.2m/z 743.4> m/z 573.6
m/z =439.4 (+Na)+ m/z =573.6 (+Na)+ m/z =338.2 (+Na)+
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Fig. 1 Molecular structures of a LPV, b RTV, and c internal standard NFVand respective fragmentations of the sodium adducts of LPV, RTV, and
NFV and MRM transition
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MALDI-MS instrument control and data analyses were
performed using Flashquant 1.0 software and Analyst 1.4.2
application software (MDS Analytical Technologies).
Assay validation
The newly developed assays were validated for the
following assay specific properties; limit of detection
(LOD), lower limit of quantification (LLOQ), linearity,
accuracy, precision, and stability of LPV and RTV in DBS/
plasma matrix using the FDA’s Guidance for Industry on
bio-analytical method validation procedure [26]. Assay
precision, accuracy, and the stability of the analytes were
determined from quality control samples (QC) prepared in
drug-free whole blood and drug-free plasma by spiking
LPV and RTV at three different concentrations of 50, 10,
and 1.0 μmol/L for DBS analysis and 4.0, 2.0, and
1.0 μmol/L for plasma analysis, respectively.
Children cohort study and sample preparation
Nineteen HIV-1-infected children (n=19) were included into
the cohort patient study during a 2-month period. Average
age of the participants was 10.2±4.0 years. Whole blood
samples from participants were collected at the outpatient
clinic of the Pediatrics department at the Erasmus MC-Sophia
Children Hospital (Rotterdam, the Netherlands). Patient blood
samples were collected in compliance with the Helsinki. The
whole blood samples from 16 of the 19 participants were
collected at approximately the same time after oral intake of
Kaletra® (mean collection time of 15.6±0.7 h). From the
three remaining patients, whole blood samples were collected
at 4.0, 18.25, and 20.50 h, respectively. Whole blood samples
were drawn by vena-puncture and collected into BD
Vacutainer EDTA tubes (Becton Dickinson, Breda, the
Netherlands). For the DBS assay, 4×25 μL of collected
whole blood was blotted onto a DBS collection card followed
by overnight drying of the DBS collection card at ambient
temperature. After the DBS collection cards were dried, they
were stored in a plastic-sealable bag (Minigrip, Lelystad, the
Netherlands) at a temperature of 4 °C. Plasma was prepared
from an aliquot of collected EDTA whole blood by
centrifugation for 6 min (400×g, 4 °C). Plasma was separated
from the red blood cell pellet transferred into a separate vial
and directly stored in a freezer at a temperature of −80 °C.
Results
Assay development
The DBS assay was developed by spiking whole blood
collected from healthy donors with LPV, RTV, and internal
standard NFV. First, extraction of the PI from the DBS
matrix was optimized by blotting aliquots of 25 μL of
spiked whole blood (20 μmol/L LPV and RTV) on DBS
collection cards. After drying, the DBS were punched out
and extracted with different organic solvent/water mixtures.
Combinations of methanol/water (MeOH/H2O) mixtures
ranged from MeOH/H2O 10:90 (v/v) to MeOH/H2O 90:10
(v/v), and the same procedure was used for acetonitrile/
water (ACN/H2O) solvent mixtures to determine optimal
conditions for PI measurement in organic/water solutions.
The best extraction results for LPV, RTV, and NFV were
obtained with ACN/H2O 80:20 (v/v) solvent mixtures. It
was observed that extracts with higher water content
(>20% v/v) were colored slightly to deep red/brown. These
extracts showed severe ion suppression during MALDI
ionization, which is probably due to extracted (oxidized)
hemoglobin. Moreover, more profound ion suppression was
observed with MeOH/H2O mixtures and less with ACN/
H2O mixtures. Ion suppression effects decreased signifi-
cantly for ACN/H2O with higher ACN content (>40% v/v).
Subsequently, we studied the maximum amount of whole
blood that could be blotted onto the DBS collection cards
without overloading the spot and causing it to spread.
Volumes of 5, 15, 25, and 40 μL of spiked whole blood
were blotted onto DBS collection cards. The 40 μL volume
resulted in a spot that had a larger diameter than the
maximum allowed by the DBS (marked by a printed circle);
thus, adjacent spots ran into each other. The optimal whole
blood amount that could be blotted was 25 μL, covering
approx. 90% of the allowed surface of printed circles.
Smaller whole blood amounts were also tested, but these
resulted in significantly higher detection limits. After
determination of the optimal amount of whole blood,
extraction volume and extraction time of DBS were studied
by the application of 50, 100, 250, and 500 μL of ACN/
H2O 80:20 (v/v) solvent mixture and extraction times of 15,
30, 45, and 60 min using sonication. The optimal DBS
extraction volume and extraction time were observed for
250 μL of ACN/H2O 80:20 (v/v) mixture and extraction
time of 30 min.
The plasma assay was developed by the application of
spiked plasma prepared from the drug-free whole blood that
was also used for the DBS assay development. To this end,
plasmawas spikedwith LPV, RTV, and NFVat a concentration
level of 1 μmol/L. Deproteinization of plasma was studied by
the application of different deproteinization agents. Studied
deproteinization agents were ACN, acetone (ACT), and
MeOH. Aliquots of 10 μL of spiked plasma were deprotei-
nized by the addition of 90 μL of ACN, ACT, or MeOH and
mixed on a vortex mixer for 1 min. Precipitated proteins were
removed by centrifugation for 10 min (2,000×g) at room
temperature, and supernatants were mixed with MALDI
matrix and spotted. The highest recoveries were observed for
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ACT deproteinization and were 93.4%, 93.2%, and 98.5% for
LPV, RTV, and NFV, respectively. Recovery rates for LPV,
RTV, and NFV using acetonitrile and methanol were approx.
80% and 13%, respectively. Furthermore, the amount of ACT
used for deproteinization was optimized, and following
amounts of ACT were tested on their deproteinization
capacities; 40, 60, 80, 90, and 100 μL for the deproteinization
of 10 μL plasma. Observed recovery rates for LPV were
36.8%, 59.7%, 114.0%, 93.8%, and 85.4%; for RTV 29.6%,
64.6%, 111.3%, 92.3%, and 77.6%; and for NFV 28.4%,
69.9%, 108.5%, 98.5%, and 86.7%, respectively. Further
deproteinization of plasma samples was performed by
deproteinization of 10 μL of plasma sample with 90 μL
of acetone.
Assay validation
Linearity of DBS and plasma assays
Selected range of whole blood and plasma-based calibrators
indicated the existence of linear relationships between the
ratio of the peak areas of LPV/NFV ratio and RTV/NFV ratio
(y) and concentration (x) of LPV and RTV in DBS and
plasma, respectively. All calibration curves showed linear
relationships between the analyte peak areas and analyte
concentration. For the plasma assay, the calibration curves
were linear between 0.05 and 4.0 μmol/L and between 0.25
and 50 μmol/L for the DBS assay, respectively. The linear
regression analyses were calculated using GraphPad Prism
software version 5.00 for windows (GraphPad Software, San
Diego, CA, USA). The regression equations of the DBS
assay were y=0.022x−0.0069 (LPV) and y=0.0165x−
0.0096 (RTV), and regression coefficients were 0.9941 and
0.9948 for LPV and RTV, respectively. The calibration curve
regression equation and regression coefficients of the plasma
assay were y=4.5131x−0.0208 (LPV) and y=30.0478x−
0.1904 (RTV), and regression coefficients were 0.9932 and
0.9965 for LPV and RTV, respectively.
LLOQ and LOD of DBS and plasma assay
The LLOQ was defined as the lowest matrix-based
calibrator of the calibration curve that could be measured
with acceptable accuracy and precision (<20% error) in
compliance with FDA regulations. The LLOQ of the DBS
assay was 0.25 μmol/L for LPV as well as RTV and
0.05 μmol/L for both analytes for the plasma assay. The
upper limits of quantification was defined as the highest
matrix-based calibrator measured and was 200 μmol/L for
LPV and RTV for the DBS assay and 4.0 μmol/L for the
plasma assay, respectively. The LODs, defined as three
times the signal-to-noise ratio of drug-free whole blood/
plasma, were 0.039 μmol/L (LPV) and 0.058 μmol/L
(RTV) for the DBS assay, and 0.0017 μmol/L (LPV) and
0.0093 μmol/L (RTV) for the plasma assay, respectively.
Within- and between-run accuracy and precision
The accuracy and precision of the DBS and plasma assay
for LPV and RTV were in good compliance with the FDA
regulations (<15/20% error and %CV). Observed accuracy
and precision results at three studied concentration levels
are listed in Table 1.
Stability of LPV and RTV
LPV and RTV were considered stable in the DBS and
plasma matrix if during conservation of the quality control
samples the decrease in concentration was <15% (expressed
as % error). The observed stability of LPV and RTV in both
biological matrices was <15% error for studied concentra-
tion levels for storage in a refrigerator (24 h, 4 °C), 20 days
in a freezer (−20 °C), and during three freeze–thaw cycles
(Tables 2 and 3).
Cross-validation of plasma assay with HPLC-UV assay
Plasma LPV and RTV concentrations observed by the newly
developed MALDI-QqQ-MS/MS plasma assay were cross-
validated with an HPLC-UV method as described previously
[27]. HPLC-UV assay determinations of plasma LPV and
RTV concentrations of participants from the cohort study
were performed at the Dept. Clinical Pharmacy (Radboud
University Nijmegen Medical Centre, the Netherlands). For
cross-validation purposes, plasma samples were separately
prepared for analysis at both laboratories, and standard
solutions were not exchanged between the laboratories.
Discussion
Currently, several papers describe the determination of PI
concentrations and other antiretroviral drugs in plasma from
HIV-1-infected patients. All papers applied HPLC or LC
assays in combination with UVormass spectrometric detection
for the determination of drug concentrations. Moreover, the
average analysis time of applied assays ranged between 5 min
to approx. 20 min per sample depending on instrumentation
and separation column used. Previously, we demonstrated that
the measurement of intracellular concentrations of LPV and
RTV in lysates of peripheral blood mononuclear cells (PBMC)
was not only very sensitive (femtomol amounts) but as
ultrafast and high-throughput [19] compared with the LC-
MS/MS assay published by Pelerine et al. [12] where an
analysis time of 20 min was reported. The MALDI-QqQ-MS/
MS assay analysis time for one sample was <15 s, which
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means that a full 96-well MALDI target plate could be
analyzed within 16- to 17-min analysis time.
For the measurement of LPV and RTV concentrations in
plasma and DBS, two new bio-analytical assays were
developed and validated. In the past, we already applied
the MALDI-QqQ-MS/MS for the analysis of LPV and RTV
in plasma samples, but this method was not validated in
compliance with the FDA regulations [19]. A cross-
validation of the DBS assay was not possible because no
HPLC-UV assay applying DBS samples was available, but
for the validation of the plasma assay, an accredited
HPLC-UV was used. The DBS and plasma assays were
developed using quality control samples, and both assays
were validated in full compliance with the FDA regulations
[26]. NFV was selected as internal standard because it was
in the past successfully used in the assay for the
intracellular PBMC concentrations for LPV and RTV [19].
Observed LOD of the DBS assay for LPV and RTV were
0.039 and 0.058 μmol/L, respectively. Observed LODs
were higher (2.8 times (LPV) and 3.6 times higher (RTV))
than reported LODs by Koal and coworkers [7]. In a
reported work by Koal et al. [7], they injected 3.125 μL
whole blood (calculated from extracted amount whole
blood) from extracted 5 μL whole blood into the LC-MS
instrumentation; this in contrast to the MALDI-QqQ-MS/
MS assay where 0.05 μL of the 25 μL DBS was used for
Table 1 Precision and accuracy of the MALDI-QqQ-MS/MS assay at three DBS and plasma concentration levels
Analyte Dried blood spots (DBS) Plasma
Nominal concentration (μmol/L)
50.0 10.0 1.0 4.0 2.0 1.0
LPV RTV LPV RTV LPV RTV LPV RTV LPV RTV LPV RTV
Within-run validationa
Mean observed concentration (μmol/L) 49.9 50.7 10.7 10.6 0.9 0.9 3.7 4.0 1.9 2.1 1.1 1.2
Accuracy (% errorb) −0.3 1.4 7.2 5.6 −8.1 −10.8 −8.6 0.5 −3.7 5.2 8.8 12.4
Precision (% CV) 4.7 6.4 11.7 11.9 16.5 12.8 7.5 12.5 10.3 13.4 11.2 8.8
Between-run validationc
Mean observed concentration (μmol/L) 51.2 49.4 10.9 9.6 1.2 1.0 3.7 4.2 2.0 2.2 1.1 1.1
Accuracy (% errorb) 2.4 −1.2 9.0 −4.3 10.1 1.0 −7.1 3.8 1.5 10.8 8.4 13.7
Precision (% CV) 11.4 9.8 12.2 11.3 18.2 18.3 12.0 14.6 13.2 12.4 12.1 11.0
aWithin-run results summarize ten spots per QC sample at each concentration level in one experiment
b % error=(mean observed concentration − nominal concentration)/(nominal concentration)×100%
c Between-run results summarize three different experiments from three consecutive days with ten spots per QC sample at each concentration level
Table 2 Stability experiments with DBS-QC samples containing LPV and RTV under different storage conditions
Nominal concentration (μmol/L) Storage conditions/time
Refrigerator (4°C)a Dessicator (20°C)a
24h 20days
LPV RTV LPV RTV
Mean (SD) % errorb Mean (SD) % errorb Mean (SD) % errorb Mean (SD) % errorb
50.0 49.9 (6.1) −0.2 48.5 (4.0) −3.0 49.7 (3.3) −0.6 49.2 (3.9) −1.6
10.0 10.5 (0.9) 5.0 10.4 (1.4) 4.0 9.4 (1.1) −6.0 10.1 (0.7) 1.0
1.0 1.1 (0.1) 10.0 0.9 (0.1) −10.0 0.93 (0.15) −7.0 1.1 (0.2) 10.0
a Results summarize ten spots per QC sample at each concentration level in one experiment
b % error=(mean observed concentration−nominal concentration)/(nominal concentration)×100%
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analysis. Moreover, the LODs of the MALDI-QqQ-MS/MS
plasma assay were 0.0017 and 0.0093 μmol/L for LPV
and RTV, respectively, comparable with LODs published
by Koal et al. [7], but they applied a total sample
amount of 1.67 μL of plasma for the LC-MS/MS
analysis and the MALDI-QqQ-MS/MS assay just
0.05 μL.
By calculating the total injected sample amounts of
0.05 μL of sample for DBS as well as plasma assay
compared with the amounts used in the reported LC-MS/
MS assay [7], it could be concluded that both
MALDI-QqQ-MS/MS assays were approx. 30 times more
sensitive. Besides the higher sensitivity, less sample
amount is needed. The more significant advantages of
the application of the MALDI-QqQ-MS/MS technology
are the ultrafast and high-throughput characteristics of this
technology. Although LODs of the MALDI-QqQ-MS/MS
assays are higher than, for example, LC-MS/MS,
MALDI-QqQ-MS/MS is sensitive enough to be applied
in the clinical practice. In very short time, TDM of DBS
and plasma concentrations from HIV-1-infected children
could be applied to verify if clinical relevant systemic
concentrations were present. Almost all patients had
therapeutically relevant concentrations of LPV in collected
plasma and via DBS collected whole blood samples.
Expected therapeutically relevant concentrations had to
range between 12 and 20 μmol/L. This relative broad
range relates if the HIV-1 child was native to Kaletra® or
already previously treated with Kaletra® [28].
The assays described here were validated by the
determination of linearity, recovery rates, within- and
between-run accuracy, and precision and stability of LPV
and RTV in both DBS and plasma matrix. The within- and
between-run accuracy and precision as well as stability
were all in compliance with FDA regulation for validation
of (new) bio-analytical assays (Tables 1, 2, and 3). After
full validation of both assays, real patient samples from a
cohort study were measured.
Patients DBS samples were extracted and analyzed by
the MALDI-QqQ-MS/MS DBS assay, and corresponding
plasma samples were prepared and analyzed in duplicate.
Patients plasma samples (n=19) were prepared according to
the optimal conditions determined. Samples (1 μL) were
spotted in fivefold onto the MALDI target plate. Patient’s
DBS were punched out in duplicate, extracted, and spotted
in fivefold onto the MALDI target plate. Comparison of
observed plasma concentrations and DBS concentrations of
LPV and RTV showed a significant correlation. The
correlation between patient’s plasma concentrations and
DBS concentrations of LPV and RTV are illustrated in
Fig. 2.
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validated with measured plasma concentrations by a
validated HPLC-UV [27] at an accredited laboratory of
the Dept. of Clinical Pharmacy (Radboud University
Nijmegen Medical Centre, the Netherlands) by calculating
the bias between both methods according to Bland–Altman
method comparison statistics [29, 30]. The differences for
LPV and RTV concentrations observed by both assays are
expressed as a Bland–Altman plot and are illustrated in
Fig. 3, and the linear regression between observed LPV and
RTV concentrations patient’s plasma samples of the HPLC-
UV- and MALDI-QqQ-MS/MS assay are also presented.
All measured differences in concentrations for LPV and
RTV for both analytical assays were between the mean of
both assays ±2 SD (95% confidence), except for one
patient’s sample (RTV) (Fig. 3d).
Both LPV and RTV concentrations were statistically
compared; however, from clinical point of view, the
protease inhibitor LPV is more important than RTV because
LPV is the active drug responsible for inhibition of the viral
HIV-1 protease. RTV, as used in the concentration in the
co-formulated Kaletra medication, acts as a kind of
pharmacokinetic booster of LPV, preventing the metabolic
degradation by drug-metabolizing CYP3A isozymes. In the
clinical practice, the LPV concentration is important for
TDM and for determination of the patient’s compliance
with the drug regimen. The MALDI-QqQ-MS/MS plasma
assay shows a slightly positive bias compared with the
HPLC-UV assay (Fig. 3b), while almost no bias is observed
with RTV (Fig. 3d) analysis. For the observed positive bias
of the LPV determination, no explanation could be given.
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Fig. 3 a Comparison of
observed LPV concentrations by
HPLC-UV assay and newly
developed MALDI-QqQ-MS/
MS assay. b Bland–Altman plot
of differences between observed
LPV concentrations by
MALDI-QqQ-MS/MS and
HPLC-UV assay. c Comparison
of observed RTV concentrations
by HPLC-UV assay and the new
MALDI-QqQ-MS/MS assay.
d Bland–Altman plot of differ-
ences between observed RTV
concentrations by
MALDI-QqQ-MS/MS and
HPLC-UV assay. Patients
(n=19) LPV and RTV plasma
concentrations were measured
by the newly developed
MALDI-QqQ-MS/MS plasma
assay and cross-validated with
an accredited HPLC-UV assay.
Solid line represents mean, and
dotted lines represent mean±2
SD (standard deviation of mean)
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In conclusion, the newly developed MALDI-QqQ-MS/MS
assays described here can be used for the sensitive and
ultrafast determination of the antiretroviral drugs LPV and
RTV in plasma and in DBS samples from HIV-1-infected
children. The assays showed significant correlations between
observed LPVand RTV concentrations in whole blood (DBS)
and in plasma. The MALDI-QqQ-MS/MS plasma assay was
successfully cross-validated with an accredited HPLC-UV
assay. The newly developed MALDI-QqQ-MS/MS DBS
assay as well the MALDI-QqQ-MS/MS plasma assay can
therefore be used for TDM and for monitoring of the patient’s
compliance to the prescribed drug regimen. The easy handling
to obtain DBS and the possibility to store the DBS collection
cards for prolonged periods should make this sampling
technique suitable for obtaining whole blood samples from
HIV-1-infected children in remote areas in developing
countries. We expect that DBS can be used in general for
quantification of metabolites, drugs, and nutrients by
MALDI-QqQ mass spectrometry.
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